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ABSTRACT: Although docetaxel is currently broadly used in prostate cancer
treatment, poor water solubility and systemic toxicity limit the dose and
duration of therapy. In this context, although different nanoplatforms have
been proposed to overcome these issues, selective therapy needs developing
methodologies to target malignant cells and minimizing the impact on healthy
tissue. We here present a novel drug delivery system obtained by covalent
conjugation of docetaxel and an anti-prostate specific membrane antigen
(PSMA) molecule (anti-FOLH1 monoclonal antibody, clone C803N) over
mesoporous silica nanoparticles. This conjugate remains stable in physiological
medium and shows high selectivity for LNCaP, a specific cell line that
overexpresses PSMA. As a consequence, cell internalization is increased by
25%. Furthermore, cytotoxic activity of the targeted system increases by 2-fold
with regard to nontargeted nanoparticles and by 2 orders with regard to the
naked drug. Conversely, no targeting effect is observed over PC3, a nonbearing
PSMA cell line. We expect that this therapeutic system shows strong potential for treating nonmetastatic prostate cancer, mostly
through intraprostatic administration.
■ INTRODUCTION
Docetaxel (DTX) is probably the most used Food and Drug
Administration (FDA)-approved drug for prostate cancer
(PCa) treatment.1 DTX is a semisynthetic anticancer agent
of the taxoid family, derived from the needles of the European
yew tree Taxus baccata, recommended as optional treatment in
patients with hormone-refractory metastatic prostate cancer.2,3
Moreover, DTX is well known for its antitumor activity against
a wide spectrum of solid tumors, including gastric, breast, lung,
ovarian, prostate, head, and neck.2−7 Several researchers have
reported that DTX binds with the tubulin, interferes with the
normal functioning of microtubules, and induces a mitotic
block in proliferating cells, resulting in apoptosis.8,9 Unfortu-
nately, DTX presents a variety of negative aspects that restrict
its use in clinical trials, essentially, poor water solubility and
severe allergic reactions.10 Moreover, its systemic toxicity limits
the dose and the duration of therapy. To overcome these
limitations, nanoplatforms based in liposomes,11 nanotubes,12
poly(D,L-lactide-co-glycolide) (PLGA) conjugates,13 and mag-
netic nanoparticles14 have been formulated and tested for DTX
delivery. In this context, mesoporous silica nanoparticles
(MSNs) are promising delivery vehicles for DTX admin-
istration due to several attractive properties, including large
surface areas, tailorable pore sizes, good biocompatibility,
uniform porosity, and easy surface functionalization.15−17 They
could be used as reservoirs for storing hydrophobic drugs
inside pores or as vehicles for the delivery of covalently linked
therapeutic agents.18 Actually, silica nanoparticles’ recent
approval by the Food and Drug Administration (FDA) for
specific clinical applications has boosted the potential of this
vehicle for the development of novel drug delivery systems
(DDSs).19
However, selective PCa therapy needs developing method-
ologies to target malignant cells and minimizing the impact on
healthy tissue. In this context, prostate-specific membrane
antigen (PSMA) is a type of II transmembrane protein
produced by prostate endothelial cells.20,21 PSMA is strongly
expressed in some PCa cell lines, including primary and
metastatic prostate cancers, normal prostate epithelium, and
tumor-associated neovasculature. Moreover, PSMA has also
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been detected in other normal and neoplastic organs, including
kidney and bladder, as well as in the neovasculature of a variety
of tumors,22,23 which makes it a promising candidate for cancer
imaging and therapy. Actually, recent studies have been
focused on cancer therapy with targeting molecules, including
antibodies, aptamers, peptides, and nucleic acids.24,25 The use
of monoclonal antibodies for tumor targeting of drug delivery
platforms is an important tool with clinical applications
because of their high affinity, specificity, and versatility. In
this strategy, antibodies bind specifically the corresponding
antigens overexpressed on the surface on cancer cells, which
can lead to selective drug accumulation at the tumor site.26
The main benefit of this strategy is the reduction of adverse
effects by selective interactions between antibody and cell-
surface receptors.27 In this sense, many papers have addressed
the use of nanoparticle/antibody conjugates for prostate cancer
therapy,28−35 although, to the best of our knowledge, there is
no report on the development of a targeted therapeutic system
against PCa based in MSNs, and only a few works have
described the use of specific antibodies incorporated in MSN
hybrids to improve the selectivity of magnetic resonance
images in PCa tissue.36−38
Herein, we present a novel DDS obtained by covalent
conjugation of DTX and an anti-PSMA molecule (aPSMA:
anti-FOLH1 monoclonal antibody, clone C803N) over MSNs.
Original protocols were developed for the covalent linking of
DTX and the antibody. The obtained conjugate showed high
selectivity for LNCaP, a specific cell line that overexpresses
PSMA. As a consequence, cell internalization was promoted by
25% with regard to the aPSMA free DDS (p < 0.0001).
Furthermore, cytotoxic activity of the aPSMA-targeted system
increased by 2-fold with regard to nontargeted nanoparticles
and by 2 orders with regard to the naked drug. Conversely, no
targeting effect was observed over PC3, a nonbearing PSMA
cell line.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of DTX Nanomedi-
cines. The synthetic steps to obtain MDX and MDAb
nanoparticles started with the esterification of succinic acid
with DTX at 2′-OH position to give DTX-Suc prodrug (Figure
Figure 1. Synthetic route to covalent modification of DTX with succinic acid to give 2′-hemissucinate docetaxel.
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1). Experimental synthetic and characterization details are
provided in the Supporting Information. Chemical structure
was confirmed by liquid-phase 1H RMN and 13C RMN
(Figures S1 and S2). Particularly, the peak at 169 ppm in the
13C RMN spectrum is assigned to the ester bond between the
succinic moiety carboxylate group and the DTX 2-hydroxyl
group.
Subsequently, incorporation of DTX and aPSMA in MSNs
was performed through a multistep surface modification, as
schematically shown in Figure 2. Initially, MSNs were
synthetized and further surface modified with (3-
aminopropyl)trimethoxysilane (APTMS) in order to function-
alize particle surface with amine groups (1.03 mmol g−1).39
Then, conjugation of these amine groups with the DTX-Suc
free carboxylic acid group via nucleophilic substitution allowed
one to covalently link DTX to the particles. Since aPSMA is a
very large molecule, we introduced a spacer in order to prevent
the possible steric hindrance and promote antibody binding to
nanoparticles. For this purpose, we coupled covalently 11-
aminoundecanoic acid (AUA) to MDX by amide bond (Figure
2). Next, aPSMA was coupled to MDU via amide bond using
carbodiimide chemistry.40
Alternatively, for cell internalization studies, nanoparticles
were functionalized with rhodamine B (RhB) instead of DTX,
according to a similar protocol depicted in Figure S3.
Transmission electron microscopy (TEM) images of MSNs
showed uniform sizes, spherical mesoporous shape, and
monodisperse distribution with an average diameter of about
114.0 ± 17.3 nm (Figure 3a). Powder X-ray measurements
revealed in all cases the typical MCM-41 nanoparticle pattern
(Figure 3b).39 MSN liquid nitrogen adsorption isotherms
fitted well to a type IV profile (Figure 3c),41 exhibiting very
high surface area and pore volume. However, the sequential
functionalization steps reduced both parameters dramatically
Figure 3. Characterization of DTX nanomedicines. (a) TEM image of unmodified MSNs. The inset shows in detail the mesostructure. (b) Powder
X-ray diffraction (XRD) patterns. (c) Nitrogen adsorption isotherms at 77 K. (d) Fourier transform infrared (FTIR) spectra of functionalized
materials showing the corresponding signals to the different organic groups incorporated. (e) Stability curve of MDX in phosphate buffer saline
(PBS) (1×, pH 7.34).
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owing to severe diffusion hindrance and partial pore collapse
(Table 1). Moreover, ζ-potential values confirmed stable
colloids in aqueous medium with high negative surface charge,
even after amine functionalization (Table 1).
FTIR spectra corroborated the successful MSN surface
modification with different functional groups (Figure 3d). All
materials show vibration bands at 1083, 795, and 466 cm−1,
which are assigned to stretching vibrations of Si−O−Si
bonds.42 MNHs show a shoulder at 2955 cm−1, which is
attributed to stretching C−H vibrations,43 and a peak at 1640
cm−1, associated with amino group bending vibration. After
conjugation of MNH particles with DTX-Suc (MDX sample),
the absorption band at 1567 cm−1 is related to CO
stretching vibration of amide moiety, proving covalent linking
between DTX prodrug and amine groups. This is also
supported by 1721 cm−1 band shifting, corresponding to the
DTX-Suc ester group, which appears now at 1733 cm−1 in
MDX. Subsequently, conjugation of AUA chain on nano-
particle amine groups (MDU material) produced different
bands associated with CO of the amide bond. Here, the
band at 1567 cm−1 in MDX was shifted to 1540 cm−1 and was
clearly more intense, and a new sharp band at 1394 cm−1
developed.40
Moreover, DTX covalent linking in nanoparticles was
checked by 13C MAS−NMR (Figure S4). The band at 178
ppm is assigned to the amide linking between MNH and DTX-
Suc, whereas the band at 172 ppm corresponds to the ester
bond between DTX and the succinate linker. Also, DTX
loading in MDX was quantified by elemental analysis, varying
in the range 9−13 wt % (Table 1). Finally, the amount of
aPSMA conjugated on the MDU surface was estimated by
Bradford protein assay over 11 μg aPSMA per mg of MDU.
Then, if we assume perfect sphere conditions, this result
involves an estimation of 427 antibody molecules per MDU
particle. These values are in agreement with other equivalent
systems described in the literature. For instance, by changing
different coupling conditions (cross-linker concentration,
antibody concentration, activation, and pH), Saha et al.
incorporated monoclonal antitroponin I antibody (mAb1)
over carboxyl group modified magnetic nanoparticles, with
variations between 2.3 and 47.4 μg of mAb1 per mg of
nanoparticles.44 Moreover, Lei et al. were able to functionalize
poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles with 9.29
mg of monoclonal antibody to human epidermal growth factor
receptor 2 (HER-2) per mg of particles.45
DTX-loaded nanoparticles may suffer from unspecific release
in physiological conditions, mostly by direct hydrolysis of the
ester bond between drug and vehicle. To validate the MDX
sample for biomedical applications, we monitored the
unspecific DTX diffusion in PBS (Figure 3e). We observed a
burst release in the first incubation hour, characterized by a
mixture of free DTX and some DTX-Suc (about 20% of this
mixture). This initial discharge was related to physisorbed
molecules within the mesopores and corresponded to 15% of
the total load. Afterward, there was very little additional DTX
release (18% after 24 h). This is consistent with the stability of
DTX covalent bonding in our system, which ensures the
specific intracellular delivery and release of the drug. DTX
stabilization on MSN pores avoids drug release into the blood
stream and extracellular matrix, and its activation is only
possible when nanoparticles are internalized into tumor
cells.46,47 In this regard, our system is more robust than
other already described models incorporating the drug by
encapsulation, such as lipid−polymer hybrids and β-cyclo-
Table 1. Physical and Chemical Properties of as-Prepared Functionalized Mesoporous Silica Nanoparticles
N2 physisorption
sample organic ligand DTX (%)a ζ-potential (mV) SBET (m
2 g−1) dpore (nm) Vpore (cm
3 g−1)
MSN OH −19.8 1106.0 4.0 1.02
MNH NH2 −16.9 860.4 3.2 0.23
MDX DTX 12.8 −14.3 359.4 3.1 0.15
MDU DTX/AUA 9.1 −10.7 76.9 2.8 0.06
MRU RhB/AUAb −10.1 513.7 3.1 0.21
aDTX determined by elemental analysis. bRhB content was estimated over 1%, as determined by elemental analysis.
Figure 4. (a) Western blot analysis detection of PSMA expression. PSMA expression was observed for LNCaP (PSMA positive) cells, but no signal
was detected for PC3 (PSMA negative) cells. (b) Confocal indirect immunofluorescence analysis in LNCaP and PC3. Cells were treated with anti-
FOLH1 monoclonal antibody (clone C803N) for 24 h, and subsequently, they were incubated with secondary labeled antibody (goat antimouse
IgG H&L-Alexa Fluor 555). Nuclei were counterstained with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI) before being observed under
a confocal laser-scanning microscope (CLSM).
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dextrin/calixarene conjugates, which present more than 50%
DTX leaching at 24 h.48,49
Detection of PSMA Protein in Prostate Cancer Cell
Lines. With the aim to confirm the expression levels of PSMA
protein in LNCaP (PSMA positive) and PC3 (PSMA negative,
used as control) cell lines, the whole extracts from cell lysis
were tested by Western blot.50,51 As shown in Figure 4a, the
PSMA protein band, at molecular weight of 110−120 kDa, is
clearly overexpressed in the LNCaP cell line, whereas it is not
expressed in PC3 cells. Moreover, the ability of aPSMA to bind
to PSMA receptors was validated by indirect immunofluor-
escence. Confocal immunofluorescence images (Figure 4b)
showed that after administration of aPSMA and a secondary
labeled antibody (goat antimouse IgG H&L-Alexa Fluor 555),
LNCaP cells showed intense red color at the cytoplasm, but no
fluorescence was detected in PC3 cells. These images
confirmed that the PSMA receptor was only located around
the LNCaP cell surface52,53 and that the aPSMA clone used to
target nanoparticles specifically binds LNCaP cell line PSMA
receptors.
Cell Internalization Study. To investigate successful
intracellular location and to confirm the influence of particle
labeling with aPSMA in cell internalization, colocalization
experiments by means of CLSM were carried out by incubating
PC3 (negative control) or LNCaP cells with 10 μg mL−1
rhodamine B nontargeted (MRB) or targeted (MRAb)
nanoparticles. Then, the acidic cell compartments were stained
with LysoTracker Green. Nanoparticles were conjugated with
RhB, and DAPI was used to stain the nucleus. Colocalization
images were acquired at different planes along the z-stack
Figure 5. (a) Colocalization studies of nontargeted (MRU) and targeted (MRAb) RhB-loaded nanoparticles in PC3 and LNCaP cell lines.
Confocal images of the same z-stacks were obtained for LysoTracker and RhB-conjugated nanoparticles and merged to demonstrate that
nanoparticles are allocated inside acidic compartments labeled by LysoTracker (dotted circles indicate colocalization regions). (b) Quantification
of MRU and MRAb nanoparticles colocalized (percentage of correlation) with acidic compartments (LysoTracker) in LNCaP and PC3 cells from
previous images. *p < 0.0001; ns = not significantly different. Scale bar: 40 μm.
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(Figure 5a). Here, yellow fluorescence indicated the
colocalization between nanoparticles and the acidic compart-
ments in both cells lines. These images demonstrated the
superior cellular internalization of MRAb in LNCaP cells,
which was attributed to the targeting force imposed by aPSMA
on the overexpressed receptor in the LNCaP cell membrane.21
On the other hand, confocal microscopy images corroborated
very little influence of aPSMA in PC3 cell internalization.
As reported previously, MSNs are passively internalized in
cancer cells by endocytosis, which is driven mostly by particle
diameter and surface charge.54−56 Although LNCaP and PC3
cell lines internalize nanoparticles through endocytosis, in the
case of LNCaP cells, aPSMA antibody interacts with a specific
entry receptor on the cell membrane, forming an antibody−
receptor conjugate that allows nanoparticles to internalize from
the cell surface to the intracellular compartment via receptor-
mediated endocytosis.57,58 Here, a quantitative estimation was
overseen by colocalization analysis. We determine colocaliza-
tion percentage by considering all optical planes along the z-
stack for each image (Figure 5b). The colocalization study of
CLSM images proved that both targeted and nontargeted
materials loaded with RhB colocalized with the acidic
compartments. However, in the case of PC3 cells, colocaliza-
tion values indicated that the presence of aPSMA on the
particle surface does not provoke any improvement of cell
uptake due to the lack of specific receptors on the cells.
Conversely, in LNCaP cells, whereas nontargeted nano-
particles showed a colocalization of 70%, in the case of
targeted nanoparticles, this value increased to 95% (p <
0.0001). This proved the strong influence of aPSMA in
promoting particle internalization mechanism in the LNCaP
cell line through specific antigen−antibody interactions,
increasing nanoparticle accumulation in cytosol. These results
confirmed the potential of using targeted MSNs with aPSMA
to deliver DTX to the tumor site in prostate cancer therapy.
Cytotoxicity Study. The cytotoxic activities of free DTX,
MDX, and MDAb were evaluated by 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT) viability assay
over PC3 and LNCaP prostate cancer cell lines. Also, for the
sake of comparison, we previously confirmed the biocompat-
ibility of the inorganic vehicle by incubating these cell lines
with MNH in the concentration range analyzed, observing that
cell viability was above 80% in all cases even at the highest
particle loading (100 μg mL−1), which corresponds to an
acceptable biocompatible profile (Figure 6).59
The expected mechanism of DTX intracellular release is the
cleavage at 2′-O-ester bond linking the taxane to the
nanoparticle by cytosolic hydrolytic enzymes (e.g., carbox-
ylates) after cell uptake.60 In this sense, all materials exhibited a
dose-dependent cytotoxic effect in the two cell lines. However,
LNCaP and PC3 showed strong resistance to DTX, even at
high drug concentration. Unfortunately, PC3 inhibition values
were always above 50%, and, consequently, IC50 parameter
could not be calculated. Conversely, in the case of LNCaP
cells, MDX and MDAb were more cytotoxic than DTX (IC50 =
0.80 ± 0.20 μg mL−1). MDX was almost 1 order more active
than the free drug against LNCaP cells (IC50 = 0.10 ± 0.02 μg
mL−1). Moreover, the incorporation of aPSMA doubled the
cytotoxic effect of nontargeted nanoparticles (MDAb, IC50 =
0.05 ± 0.01 μg mL−1). Here, it is noticeable that LNCaP cells
were much more sensitive to DTX than PC3, which supports
the targeting effect driven by aPSMA over DTX containing
nanoparticles.
It has been reported that DDS conjugation with aPSMA
antibodies provides a substantial improvement in the capacity
of these PSMA-targeted nanovehicles to bind specifically to
cells that express PSMA receptors,37,61 enhancing the cytotoxic
effect of the nanoplatforms.35 Consequently, our data
suggested that selectivity and high affinity of MDAb can be
attributed to the specific interaction between antibody
conjugated nanoparticles loaded with DTX and the receptor
expressed on the LNCaP cell membrane. To the best of our
knowledge, this is the first report of a targeted DTX
nanomedicine against PCa based in MSNs, which has shown
improved cytotoxic activity in comparison to the free drug. In
addition, the incorporation of aPSMA antibody promotes drug
delivery to malignant cells and minimizes the effect of naked
DTX over healthy tissue, allowing the administration of higher
doses of the drug in the case of chemotherapy resistance. This
is particularly relevant in this type of cancer, as PSMA
expression is correlated with tumor invasiveness, but, in the
case of intraprostatic administration, the targeting effect can
promote local accumulation on malign nodules, improving
DTX cytotoxic effect with no significant damage over the
surrounding tissue.62
■ CONCLUSIONS
We have formulated a novel DDS for selective delivery of DTX
into PCa cell lines bearing PSMA receptors through covalent
bonding of the drug and specific targeting by anti-FOLH1
Figure 6. In vitro MTT cell viability assays in LNCaP (a) and PC3 (b) cell lines after incubation with variable concentrations of MNH, DTX,
MDX, and MDAb (MDX and MDAb are expressed as equivalent DTX). All samples were incubated for 72 h. Each value represents the mean ±
standard error (SEM) of three independent experiments.
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monoclonal antibody (clone C803N). This nanoplatform
remains stable in physiological conditions and promotes
DTX cell internalization by 25% over LNCaP cells.
Furthermore, cytotoxic activity is increased by 2 orders with
regard to free DTX and 2-fold regarding nontargeted
nanoparticles. At this point, the specific antigen−antibody
interactions drive efficient particle cell internalization, whereas
the high DTX loading capability of MSNs provides improved
cytotoxic activity even at low dose and stimuli-responsive
intracellular drug discharge due to the sensitivity of this DDS
to cytosolic hydrolytic enzymes. These properties lead to a
therapeutic system with strong potential for treating patients
with nonmetastatic PCa, mostly when focusing on intra-
prostatic administration. Currently, we are extending this study
to in vivo testing over LNCaP or PC3 xenografts in male mice.
■ MATERIAL AND METHODS
Materials. All chemical reagents were supplied by Sigma-
Aldrich except DTX (Carbosynth), 1-[bis(dimethylamino)-
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexa-
fluorophosphate (HATU, Fluorochem), N,N′-dimethylforma-
mide (DMF, Acros Organics), tetraethyl orthosilicate (TEOS,
Merck Millipore), and (3-aminopropyl)trimethoxysilane
(APTMS, ABCR). High-performance liquid chromatography
(HPLC)-grade solvents were purchased from Scharlab, and
water was deionized to 18.2 MΩ cm−1 using a Milli-Q pack
system.
Human prostate cancer cells lines (PC3 and LNCaP) were
purchased from the American Type Culture Collection
(ATCC, Rockville, MD). RPMI 1640 medium was obtained
from Lonza. Penicillin/streptomycin was purchased from GE
Healthcare HyClone. Fetal bovine serum was obtained from
Sigma-Aldrich. Anti-FOLH1 monoclonal antibody (clone
C803N, aPSMA) was purchased from Creative Diagnostics.
Tripsina−ethylenediaminetetraacetic acid 0.25% was obtained
from Merck Millipore. 4′,6-Diamidine-2′-phenylindole dihy-
drochloride (DAPI) and LysoTracker Green were purchased
from Invitrogen, and DRAQ5 was supplied by from BioStatus.
Analytical Techniques. 1H NMR and 13C NMR spectra
were recorded on a Bruker AV300 Ultrashield spectrometer.
1H NMR spectra were acquired at 300 MHz using pulses of 15
μs and a recycle time of 1 s. Data for 1H spectra are reported as
follows: chemical shift, multiplicity (s = singlet; d = doublet;
dd = doublet of doublet; t = triplet; dt = doublet of triplet; m =
multiplet), and integration. Both 1H and 13C experiments were
carried out using tetramethylsilane as chemical shift reference.
Reverse-phase high-performance liquid chromatography (RP-
HPLC) analysis was performed on Agilent HPLC 1220 Infinity
LC coupled to a variable-wavelength detector 1260 Infinity
with a C18 reverse-phase column (Mediterranea Sea 18, 5 μm,
25 × 0.46 mm, Teknokroma, Sant Cugat del Valleś, Spain).
The products were eluted utilizing a constant solvent mixture
(CH3CN/H2O-trifluoroacetic acid pH 4.5 60:40 v/v) at 0.65
mL min−1. Quadrupole time-of-flight mass spectra (Q-TOF)
were recorded on Aquity UPLC Waters coupled with Xevo Q-
TOF MS with an Aquity UPLC BEH C18 (1.7 μm, 50 × 21
mm) column and using positive electrospray ionization. The
products were eluted utilizing a constant solvent mixture 60:40
v/v (solvent A = 0.1% CF3COOH/CH3CN; solvent B = H2O)
at 0.5 mL min−1.
Synthesis of Amine Functionalized MSNs. A standard
method with some modifications was used for the synthesis of
unmodified MSNs.39 First, 1.00 g of hexadecyltrimethylammo-
nium bromide was dissolved in water/ethanol (476 mL, 7:1 v/
v). Subsequently, 5 mL of NaOH 1 M was added, and the
temperature was raised to 75° C with strong stirring. Then, 5.0
mL of TEOS was added to the solution and stirred for 2 h at
75 °C. The resulting mixture was cooled in ice, filtered off,
washed with distilled water and methanol, and dried in air. To
remove the surfactant, the solid powder was refluxed in 150
mL of HCl solution in ethanol (0.25N) for 24 h. The white
solid was collected by filtration and refluxed again in 150 mL of
hydrochloric acid (HCl) solution in ethanol (0.25N) for 24 h.
The solid was filtered, washed with distilled water and ethanol,
and dried overnight at room temperature under vacuum.
MSNs derivatized with amine groups (MNHs) were
prepared by surface functionalization with APTMS. First,
500 mg of MSN was suspended in 15 mL of anhydrous
toluene, and 1.0 mL of APTMS was added to the mixture
solution. The suspension was heated at 120 °C under argon for
24 h. Then, it was cooled down to room temperature, the
product was filtered off, washed with toluene and methanol,
and dried at room temperature under vacuum.
Synthesis of 2′-Hemissucinate Docetaxel. For DTX
incorporation on MNHs, a prodrug with succinic acid was
firstly prepared. For this purpose, DTX was reacted at 2′-OH
position with succinic anhydride to give the corresponding
ester (2′-hemissucinate docetaxel).63 This process is detailed
and depicted in the Supporting Information.
Incorporation of Docetaxel to Amine Functionalized
MSNs. To a suspension containing 240 mg of MNH in a
mixture of anhydrous dichloromethane and DMF (20 mL, 9:1
v/v), DTX-Suc (217 mg, 0.24 mmol), HATU (92 mg, 0.24
mmol), and N,N′-diidopropylethylamine (DIPEA, 42 μL, 0.24
mmol) were added one at a time. Afterward, the reaction was
stirred at room temperature for 2 days under argon
atmosphere. Then, the resulting mixture was filtered off and
washed with dichloromethane, water, and methanol and finally
dried overnight at room temperature under vacuum to give
240 mg of MSN modified with covalently linked DTX (MDX).
Incorporation of Rhodamine B to Amine Function-
alized MSNs. First, 220 mg of MNH was suspended in a
mixture of anhydrous dichloromethane and DMF (10 mL,
8:2), and then rhodamine B (RhB, 2.2 mg, 0.0046 mmol),
HATU (11 mg, 0.03 mmol), and DIPEA (6 μL, 0.03 mmol)
were added to the solution. The mixture was stirred at room
temperature for 2 days under argon atmosphere. After this
time, the resulting mixture was filtered off and washed with
dichloromethane, water, and methanol and finally dried
overnight at room temperature under vacuum to give 230
mg of MSN modified with covalently linked rhodamine B
(MRB).
Incorporation of Anti-FOLH1 Monoclonal Antibody
to Amine Functionalized MSNs. Anti-FOLH1 monoclonal
antibody (clone C803N, aPSMA) was linked on MDX and
MRB materials. For this purpose, 100 mg of MDX or MRB was
suspended in an anhydrous mixture of dichloromethane and
DMF (10 mL, 8:2). Subsequently, 11-aminoundecanoic acid
(AUA) (39 mg, 0.10 mmol), HATU (21 mg, 0.10 mmol), and
DIPEA (18 μL, 0.10 mmol) were added to the solution. The
mixture was stirred at room temperature for 2 days under
argon atmosphere. After this time, the resulting mixture was
filtered off and washed with dichloromethane, water, and
methanol and finally dried overnight at room temperature
under vacuum to give the corresponding derivatives containing
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AUA covalently linked, MDU (with DTX), and MRU (with
RhB).
MDAb (MSNs containing DTX and aPSMA) and MRAb
(MSNs containing RhB and aPSMA) were separately
synthesized via covalent conjugation between the carboxylic
acid group of antibody and the amine group of nanoparticles
using a procedure described in the literature.40 For this
purpose, 10 μL of anti-PSMA antibody (5 mg mL−1) was
suspended in 100 μL of 2-(N-morpholino)ethanesulfonic acid
buffer (0.1 M, pH 6.0). N-Hydroxysuccinimide and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide were separately added
to the solution, and the mixture was stirred at room
temperature for 30 min. After this time, 1 mg of MDU or
MRU was dispersed in 1 mL of phosphate buffer saline (PBS,
1×, pH 8.5) and added to the solution of aPSMA. The
suspension was stirred at room temperature for 2 h. Afterward,
the resulting MDAb or MRAb was washed (three times) with
PBS (1×, pH 7.4) and collected. The amount of conjugated
antibody in the different materials was quantified by using the
Bradford protein assay to determine total protein concen-
tration.
Material Characterization. Synthesized nanoparticle size
distribution and ζ-potential in aqueous dispersion were
determined by dynamic light scattering using Zetasizer Nano
ZS (Malvern Instruments Ltd., Worcestershire, United King-
dom). Dried material solutions in deionized water at a
concentration of 5 μg mL−1 were prepared, and measurements
were performed at 25 °C and 173° scattering angle. Powder X-
ray diffraction (XRD) patterns were collected in a Philips
X’Pert diffractometer equipped with a graphite monochroma-
tor, operating at 40 kV and 45 mA. Nanoparticle morphology
was investigated by transmission electron microscopy (TEM)
in a JEOL JEM 2100F microscope operating at 200 kV.
Nitrogen gas adsorption isotherms were measured in a
Micromeritics Flowsorb apparatus. Surface area calculations
were performed using the Brunauer−Emmett−Teller (BET)
method, whereas pore size distribution was calculated
according to the Kruk−Jaroniec−Sayari estimation.64 Fourier
transform infrared (FTIR) spectra were recorded at room
temperature in the 400−3900 cm−1 region with a Nicolet 205
× B spectrophotometer, equipped with a Data Station, at a
spectral resolution of 1 cm−1 and accumulations of 128 scans.
MAS−NMR spectra were obtained at room temperature on a
Bruker AV400 spectrometer, with a 7 mm Bruker BL-7 probe
at sample spinning rate of 5 kHz. The 1H to 13C cross-
polarization spectra were acquired by using a 90 pulse for 1H
of 5 μs, a contact time of 5 ms, and a recycle of 3 s and referred
to adamantine. Carbon content in nanoparticles, correspond-
ing to the different organic functionalizations, was monitored
by elemental analysis (FISONS, EA 1108 CHNS-O), and
aPSMA loading in nanoparticles was exactly measured by
Bradford protein assay. For this purpose, 5 μL of aliquots of
standard albumin (to obtain a calibration curve) and samples
were pipetted in a 96-well plate. Then, 200 μL of Bradford
reagent was added to each well and mixed. After 5 min, the
absorbance was measured with a VICTOR2 Wallac 1420
Multilabel HTS Counter PerkinElmer (Northwolk, CT) at the
wavelength of 570 nm. To determine the adsorbed amount of
antibody by difference calculation, we used the supernatant of
the reaction between the antibody and nanoparticles at initial
time (before being added to the nanoparticles) and once the
reaction was complete.
Stability Testing. DTX nonspecific release in PBS (1×,
pH 7.34) was monitored by reversed-phase HPLC. For this
purpose, 5 mg of MDX was dispersed in PBS (1 mL) and
incubated at 37 °C at different times in a Thermomixer with
strong stirring (1500 rpm). Afterward, samples were
centrifuged (14 000 rpm, 15 min), and the supernatants were
retired. All residues were washed twice with methanol and
freeze-dried. Finally, solutions were reconstituted with
methanol (1 mL), and DTX was analyzed. All determinations
were done in triplicate, and the mean ± standard deviation was
determined in every case.
Western Blotting. LNCaP and PC3 cells were lysed using
200 μL of cold Triplex buffer in the presence of a protease
inhibitor cocktail (cOmplete, Roche, Mannheim, Germany).
After that, the protein concentration was determined using a
Bradford protein assay. Protein samples (15 μg proteins) were
separated by electrophoresis on 4−20% mini-protean TGX gel
(Bio-Rad Laboratories) and transferred to a poly(vinylidene
difluoride) membrane. Then, the membrane was blocked with
nonfat dry milk for 1 h and incubated with primary mouse anti-
PSMA human antibody (aPSMA) and with secondary goat
antimouse IgG antibody for 1 h. Finally, band intensity was
detected by chemiluminescence with an enhanced chemilumi-
nescence kit (Bio-Rad).
Indirect Immunofluorescence. To confirm the detection
of cell-surface expression of PSMA on the LnCaP cell line,
indirect immunofluorescence staining was performed. Briefly,
PC3 and LNCaP cells were plated on 4-well Lab-Tek chamber
slides for 24 h to allow cells to attach. Later, cells were washed
with PBS (1×, pH 7.34) and fixed in 4% paraformaldehyde for
20 min at room temperature. After washing, cells were
incubated with aPSMA overnight and, subsequently, with
goat antimouse 555 monoclonal antibody for 1 h. Then, cells
were washed with PBS, and the nuclei were counterstained
with DAPI (final concentration of 1 μg mL−1) for 5 min.
Finally, cells were washed with PBS (1×, pH 7.34), and the
chamber slide was mounted on glass microscope slides with
Fluoromount Aqueous mounting medium (Sigma-Aldrich),
and the samples were acquired on a Leica TCS-SP2-AOBS
confocal microscope (Leica Microsystems CMS GmbH,
Germany).
Cell Internalization Study. Nanoparticle uptake by cells
was monitored by laser confocal scanning microscopy
(CLSM). For this purpose, 1 × 105 cells PC3 and LNCaP
were seeded on four chamber Slide Lab-Tek for 24 h to allow
cells to attach. For cellular uptake studies, cells were treated
with 10 μg mL−1 MRB and MRAb nanoparticles for 24 h at 37
°C. Cells incubated in the absence of MRB and MRAb were
used as control. After 24 h, LysoTracker Green was added at a
concentration of 10 μg mL−1, and subsequently, cells were
fixed in 4% paraformaldehyde for 20 min at room temperature.
After that, cells were washed (three times) with PBS, and the
nuclei were counterstained with DAPI (final concentration of 1
μg mL−1) for 5 min. Finally, cells were washed (three times)
with PBS (1×, pH 7.34), and coverslips were mounted on glass
microscope slides with Fluoromount Aqueous mounting
medium (Sigma-Aldrich). The samples were visualized on a
Leica TCS-SP2-AOBS confocal microscope (Leica Micro-
systems CMS GmbH, Germany).
Cytotoxicity Study. The effect of the different materials
on cell metabolic activity was determined using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) colorimetric assay. PC3 and LNCaP cells were seeded
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in a 96-well plate at a density of 10 000 cells per well and
cultured in 5% CO2 at 37 °C for 24 h. Then, cells were treated
with free DTX (stock solution in dimethyl sulfoxide), MDX
(stock solution in culture medium), and MDAb (stock
solution in culture medium), with final doses ranging from
0.005 to 100 μg mL−1 in DTX equivalents and empty MNH
during 72 h. At the end of this period, 10 μL of MTT solution
(5 mg mL−1) in culture medium was added into each well and
incubated for another 4 h. The supernatant in each well was
carefully removed, and 150 μL of isopropanol was added to
dissolve formazan crystals. Absorbance was measured with a
Perkin Wallac 1420 VICTOR2 V Multilabel HTS Counter
Microplate Reader (Northwolk, CT) at the wavelength of 570
nm. For every sample, three independent experiments were
performed, and each experiment was carried out in triplicate.
Statistical Analysis. Colocalization experiment quantifica-
tion was performed by using Leica LAS X software. Differences
between the groups in confocal analysis were determined by
unpaired Student’s t test. The IC50 value represents the
concentration of each compound required to produce 50%
inhibition. GraphPad PRISM 6 (GraphPad Software, Inc.)
program was used for data statistical analysis. Significant
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